Key Insights

Highlights

Success Rate

92% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 30/100

Termination Rate

5.3%

1 terminated out of 19 trials

Success Rate

91.7%

+5.2% vs benchmark

Late-Stage Pipeline

32%

6 trials in Phase 3/4

Results Transparency

27%

3 of 11 completed with results

Key Signals

3 with results92% success

Data Visualizations

Phase Distribution

18Total
Not Applicable (4)
Early P 1 (1)
P 1 (1)
P 2 (6)
P 3 (3)
P 4 (3)

Trial Status

Completed11
Unknown3
Active Not Recruiting1
Not Yet Recruiting1
Terminated1
Withdrawn1

Trial Success Rate

91.7%

Benchmark: 86.5%

Based on 11 completed trials

Clinical Trials (19)

Showing 19 of 19 trials
NCT04930107Early Phase 1Active Not RecruitingPrimary

Vulvovaginal Candidiasis in Canadian Females

NCT07521137Phase 2Not Yet RecruitingPrimary

Biweekly Long-term Occidiofungin Study for Suppression of Mycotic Recurrence

NCT06572488Not ApplicableCompletedPrimary

Non-ablative Er:YAG for Recurrent Candidiasis

NCT03075046Not ApplicableUnknownPrimary

Use of 405nm Blue Light Emitting Diode in the Treatment of Women With Vulvovaginal Candidiasis: a Clinical Trial

NCT05367089Phase 3RecruitingPrimary

The Effect of Medical Grade Honey Formulation (L-Mesitran) Administration on Recurrent Vulvovaginal Candidiasis Symptoms

NCT05059145Phase 2UnknownPrimary

A Clinical Trial for Chlorhexidine as Treatment for Vulvovaginal Candidiasis

NCT04626258Phase 4UnknownPrimary

Fluconazol Versus Medical Honey in the Treatment of Recurrent Vulvovaginal Candidiasis

NCT02733432Phase 2CompletedPrimary

RADIANT: CD101 vs Standard of Care in Subjects With Acute Vaginal Yeast Infections

NCT03975569Not ApplicableCompletedPrimary

Study of the Vaginal Microbiota and the Potential of a Vaginal Probiotic Cream in Vaginal Candidosis

NCT03167957Phase 2Withdrawn

Efficacy and Safety of Oral Encochleated Amphotericin B (CAMB) in the Treatment of Fluconazole-Resistant Vulvovaginal Candidiasis

NCT02971007Phase 2Completed

Safety and Efficacy of Oral Encochleated Amphotericin B (CAMB/MAT2203) in the Treatment of Vulvovaginal Candidiasis (VVC)

NCT01891331Phase 2CompletedPrimary

A Study to Evaluate the Efficacy and Safety of Oral VT-1161 in Patients With Acute Vaginal Candidiasis (Yeast Infection)

NCT02859493Not ApplicableTerminatedPrimary

Effect of Saccharomyces Cerevisiae on Vulvo-vaginal Candidiasis

NCT02888197CompletedPrimary

Non-Interventional Extension to Investigate Recurrence of Vulvovaginal Candidiasis and Candida Colonization

NCT02730494Phase 1CompletedPrimary

Study Evaluating the Optimal Dosage for Equivalence Between Lcr Regenerans® Capsules and Tablets (Lactobacillus Rhamnosus Lcr35®) on the Vaginal Flora Colonisation

NCT02180828Phase 4CompletedPrimary

Clotrimazole Vaginal Tablet vs Fluconazole for Severe Vulvovaginal Candidiasis

NCT02251093Phase 3CompletedPrimary

Study of the Efficacy and Tolerance of Intra-vaginal Treatment With a Total Freeze-dried Culture of Lcr Regenerans® in the Prevention of Relapses of Recurrent Vulvovaginal Candidiasis

NCT01293643Phase 3Completed

A Study to Compare the Efficacy and Safety of a Combination of Ketoconazole and Clindamycin Compared to Tetracycline/Amphotericin B Combination Cream for the Treatment of Bacterial Vaginosis and Vaginal Candidiasis (P08077)

NCT02248506Phase 4CompletedPrimary

Epidemiological Study About the Evolution of Patients Treated for an Acute Episode of Vulvovaginal Candidiasis

Showing all 19 trials

Research Network

Activity Timeline